Welcome to our dedicated page for HUTCHMED (China) SEC filings (Ticker: HMDCF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HUTCHMED (China) Limited filings document foreign private issuer reporting through Form 6-K submissions, annual report materials, annual general meeting notices, circulars, proxy forms and depositary voting instructions for holders of American depositary shares. The disclosures identify HUTCHMED as a commercial-stage biopharmaceutical company developing targeted therapies and immunotherapies for cancer and immunological diseases.
Its regulatory documents also cover total voting rights, ordinary share and ADS equivalence, shareholder voting mechanics, governance materials and company announcements on drug-development programs such as sovleplenib and HUTCHMED-discovered oncology compounds.
HUTCHMED has begun a global Phase I/IIa clinical trial of HMPL-A580, its second next-generation Antibody-Targeted Therapy Conjugate (ATTC), in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first patient was dosed on March 4, 2026.
HMPL-A580 links a highly selective PI3K/PIKK small-molecule inhibitor to an anti-EGFR antibody, aiming to exploit synergy between PAM pathway inhibition and EGFR blockade. The study’s dose-escalation phase will determine the recommended dose, followed by expansion cohorts to further assess safety and preliminary anti-tumor activity.
HUTCHMED has begun a global Phase I/IIa clinical trial of HMPL-A580, its second next-generation Antibody-Targeted Therapy Conjugate (ATTC), in patients with unresectable, advanced or metastatic solid tumors in China and the US. The first patient was dosed on March 4, 2026.
HMPL-A580 links a highly selective PI3K/PIKK small-molecule inhibitor to an anti-EGFR antibody, aiming to exploit synergy between PAM pathway inhibition and EGFR blockade. The study’s dose-escalation phase will determine the recommended dose, followed by expansion cohorts to further assess safety and preliminary anti-tumor activity.
HUTCHMED (China) Limited has scheduled the release of its 2025 final results for March 5, 2026. The announcement will be made at 6:00 am EST, 11:00 am GMT and 7:00 pm HKT, giving investors in major markets simultaneous access.
Management will host two webcast presentations for analysts and investors to review the results and take questions. An English webcast is set for 8:00 am EST on March 5, 2026, and a Putonghua webcast for the Hong Kong and mainland China audience will follow on March 6, 2026. Live and replay access will be available via the company’s website.
HUTCHMED (China) Limited has scheduled the release of its 2025 final results for March 5, 2026. The announcement will be made at 6:00 am EST, 11:00 am GMT and 7:00 pm HKT, giving investors in major markets simultaneous access.
Management will host two webcast presentations for analysts and investors to review the results and take questions. An English webcast is set for 8:00 am EST on March 5, 2026, and a Putonghua webcast for the Hong Kong and mainland China audience will follow on March 6, 2026. Live and replay access will be available via the company’s website.